Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Subcutaneous Neuromodulation System (SNS) and Implantable ElectroAcupuncture Device (IEAD): Emerging Alternatives to ED Treatment

Reporter: Aviva Lev-Ari, PhD, RN

Electroacupuncture Implant Treats Erectile Dysfunction

Mon, 07/20/2015 – 9:03am

Melissa Fassbender, Editor, PD&D, @melfass

Valencia Technologies Corporation, a medical technology corporation, currently holds a patent for subcutaneous neuromodulation system (SNS), which emits a low-powered electrical stimulus that communicates with the brain to help regulate blood pressure.

Building on this technology, the company has now been assigned a patent for an implantable electroacupuncture device (IEAD) for treating erectile dysfunction.

The device is coin-sized, self-contained, leadless, and has at least two electrodes attached to an outside surface of its housing. It works by applying electroacupuncture (EA) stimulation pulses at various “target tissue locations.”

According to the patent, “The device generates stimulation pulses in accordance with a specified stimulation regimen. Power management circuitry within the device allows a primary battery, having a high internal impedance, to be used to power the device.”

Its low duty cycle and power management allow the IEAD to perform its intended function for several years – meaning no more pills.

SOURCE:

http://www.mdtmag.com/news/2015/07/electroacupuncture-implant-treats-erectile-dysfunction?et_cid=4684419&et_rid=461755519&type=cta

Current And Future Applications – Valencia Technologies Corporation

• Hypertension
• Pain
• Depression
• Schizophrenia
• Vascular Dementia
• Heart Failure
• Erectile Dysfunction

http://valenciatechnologies.com/?

impedance characteristics, and applies current at a low duty cycle. The patent applications are trying to protect the use of the basic technology described as the stimulation of nerves X and Y to address chronic condition Z.  The chronic conditions for protection are hypertension, heart failure, coronary artery disease, angina,myocardial ischemia, Parkinson’s disease, essential tremor, obesity, dyslipidemia, depression, schizophrenia, post traumatic stress disorder, anxiety, erectile dysfunction, and chronic low back pain. For its invention, Valencia holds seven issued U.S. patents and ten patent applications under review by the United States Patent and Trademark Office.

SOURCE

http://valenciatechnologies.com/patents/